Citius Pharmaceuticals (OTCQB: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets. Citius products offer new and expanded indications for previously approved pharmaceutical products as a means to achieve leading market position or market exclusivity. By using previously approved drugs with substantial safety and efficacy data, Citius seeks to reduce the risks associated with pharmaceutical product development. Citius is currently advancing two proprietary product candidates, our Mino-Lok™ product and a Hydrocortisone-Lidocaine formulation. Citius believes the markets for its products are large and underserved by the current standard of care.

Mino-Lok™

Our Mino-Lok™ product may provide a superior alternative to removing and replacing central venous catheters (CVCs). Of the approximately 7 million CVCs used annually, about 500,000 or 7% become contaminated leading to serious, life threatening infections called catheter-related blood stream infections (CRBSIs). A 90 patient Phase 2b clinical study using our Mino-Lok™ product demonstrated sufficient safety to proceed to a pivotal Phase 3 trial. Our Mino-Lok™ product has received a U.S. FDA QIDP designation.

Hydro-Lido

Hydro-Lido is a topical formulation of hydrocortisone and lidocaine that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. In the United States, hemorrhoids affect nearly 5% of the population, with approximately 10 million patients annually reporting symptoms of hemorrhoidal disease; approximately one-third visit a physician for evaluation and treatment of their hemorrhoids. Citius has recently completed Phase 2a studies for its hydrocortisone-lidocaine topical therapy.